Altamira Therapeutics Ltd
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses… Read more
Altamira Therapeutics Ltd (CYTO) - Total Assets
Latest total assets as of March 2024: $7.69 Million USD
Based on the latest financial reports, Altamira Therapeutics Ltd (CYTO) holds total assets worth $7.69 Million USD as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Altamira Therapeutics Ltd - Total Assets Trend (2011–2023)
This chart illustrates how Altamira Therapeutics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Altamira Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2023)
Altamira Therapeutics Ltd's total assets of $7.69 Million consist of 15.9% current assets and 84.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.0% |
| Accounts Receivable | $74.82K | 1.0% |
| Inventory | $-74.82K | -1.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.89 Million | 50.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2023)
This chart illustrates how Altamira Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Altamira Therapeutics Ltd's current assets represent 15.9% of total assets in 2023, a decrease from 73.7% in 2011.
- Cash Position: Cash and equivalents constituted 8.0% of total assets in 2023, down from 55.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 26.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 50.6% of total assets.
Altamira Therapeutics Ltd Competitors by Total Assets
Key competitors of Altamira Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Altamira Therapeutics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Altamira Therapeutics Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Altamira Therapeutics Ltd is currently not profitable relative to its asset base.
Altamira Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 0.32 | 3.54 |
| Quick Ratio | 1.46 | 0.27 | 3.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $334.24K | $ -3.64 Million | $ 4.53 Million |
Altamira Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Altamira Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.08 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 22.1% |
| Total Assets | $7.69 Million |
| Market Capitalization | $317.98K USD |
Valuation Analysis
Below Book Valuation: The market values Altamira Therapeutics Ltd's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Altamira Therapeutics Ltd's assets grew by 22.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Altamira Therapeutics Ltd (2011–2023)
The table below shows the annual total assets of Altamira Therapeutics Ltd from 2011 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $7.69 Million | +22.08% |
| 2022-12-31 | $6.30 Million | -66.54% |
| 2021-12-31 | $18.84 Million | -9.43% |
| 2020-12-31 | $20.80 Million | +125.44% |
| 2019-12-31 | $9.23 Million | -6.59% |
| 2018-12-31 | $9.88 Million | -44.59% |
| 2017-12-31 | $17.83 Million | -50.01% |
| 2016-12-31 | $35.66 Million | -32.48% |
| 2015-12-31 | $52.81 Million | -11.23% |
| 2014-12-31 | $59.49 Million | +126.62% |
| 2013-12-31 | $26.25 Million | +2932.28% |
| 2012-12-31 | $865.76K | -36.54% |
| 2011-12-31 | $1.36 Million | -- |